Cancer immunology, immunotherapy : CII

Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.

Pub Date : 2025-07-21 DOI: 10.1007/s00262-025-04130-z Song Guan, Hui Wang, Zhaoxin Chen, Fengrui Guo, Guozhen Yi, Xingyu Du, Jingjing Yan, Cuimeng Tian

Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation.

Pub Date : 2025-07-15 DOI: 10.1007/s00262-025-04097-x Dong Zheng, Bingxin Zhang, Quanqiang Wang, Sisi Zheng, Yibo Xia, Ziwei Zheng, Zhili Lin, Shuxia Zhu, Xinyi Zhang, Luning Cui, Hansen Ying, Tianyu Zhang, Shujuan Zhou, Zixing Chen, Enqing Lan, Yu Zhang, Xuanru Lin, Jingjing Chen, Honglan Qian, Xudong Hu, Yan Zhuang, Zuoting Xie, Xiangjing Zhou, Zhouxiang Jin, Songfu Jiang, Yongyong Ma

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study.

Pub Date : 2025-07-15 DOI: 10.1007/s00262-025-04129-6 Shuofeng Li, Guanhua Yu, Mingming Wang, Shi Feng, An Zhang, Yu Wu, Zixiang Zhou, Shanshan Wang, Yihong Zhang, Mingjian Piao, Chengjie Li, Ziyu Xun, Boyu Sun, Jiongyuan Li, Nan Zhang, Hu Li, Yongliang Sun, Wen Zhang, Zhenyu Zhu, Haitao Zhao